Effects of L-carnitine in patients with hepatic encephalopathy

World Journal of Gastroenterology

Volumn 11, Issue 45, 2005, Pages 7197-7202

  Malaguarnera, Mariano ^a   Pistone, Giovanni ^a   Elvira, Rampello ^a   Leotta, Carmelo ^a   Scarpello, Linda ^a   Liborio, Rampello ^a  

^a UNIVERSITY OF CATANIA   (Italy)

Author keywords

Ammonia; Carnitine; Cirrhosis; Hepatic encephalopathy; Treatment

Indexed keywords

AMMONIA; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARNITINE; DIURETIC AGENT; PLACEBO;

ADULT; ALCOHOLISM; AMMONIA BLOOD LEVEL; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFICACY; FEMALE; HEPATIC ENCEPHALOPATHY; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE;

EID: 31544477426     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v11.i45.7197     Document Type: Article

References (32)

1. Lockwood AH, Yap EW, Wong WH Cerebral ammonia metabolism in patients with severe liver disease and minimal hepatic encephalopathy. J Cereb Blood Flow Metab 1991; 11: 337-341
2. Blei AT. Brain oedema and portal-systemic encephalopathy. Liver Transpl. 2000; 6: S14-20
3. O'Connor JE, Costell M, Grisolia S. Prevention of ammonia toxicity by L-carnitine: metabolic changes in brain. Neurochem Res 1984; 9: 563-570
4. Therrien G, Rose C, Butterworth J, Butterworth RF. Protective effect of L-carnitine in ammonia-precipitated encephalopathy in the portacaval shunted rat. Hepatology 1997; 25: 551-556
5. Matsuoka M, Igisu H, Kohriyama K, Inoue N. Suppression of neurotoxicity of ammonia by L-carnitine. Brain Res. 1991; 567: 328-331
6. Malaguarnera M, Pistone G, Astuto M, Dell'Arte S, Finocchiaro G, Lo Giudice E, Pennisi G. L-Carnitine in the treatment of mild or moderate hepatic encephalopathy. Dig Dis 2003; 21: 271-275
7. Bremer J. The role of carnitine in cell metabolism. In: De Simone C, Famularo G. (eds). Carnitine Today. Springer-Verlag, Heidelberg, 1997; pp. 1-37
8. Kaiser S, Gerok W, Haussinger D. Ammonia and glutamine metabolism in human liver slices: new aspects on the pathogenesis of hyperammonaemia in chronic liver disease. Eur J Clin Invest 1988; 18: 535-542
9. Gebhardt R, Reichen J. Changes in distribution and activity of glutamine synthetase in carbon tetrachloride-induced cirrhosis in the rat: potential role in hyperammonemia. Hepatology 1994; 20: 684-691
10. Kircheis G, Nilius R, Held C, Berndt H, Buchner M, Gortelmeyer R, Hendricks R, Kruger B, Kuklinski B, Meister H, Otto HJ, Rink C, Rosch W, Stauch S. Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double-blind study. Hepatology 1997; 25: 1351-1360
11. Conn HO, Liebertahl MM. The hepatic coma syndromes and lactulose. Baltimore: Williams and Wilkins, 1979: 1-121
12. Conn HO. Trailmaking and number connection tests in the assessment of mental state in portal systemic encephalopathy. Am J Dig Dis 1977; 22: 541-550
13. Atterbury CE, Maddrey WC, Conn HO. Neomycin-sorbitol and lactulose in the treatment of acute portal-systemic encephalopathy. A controlled, double-blind clinical trial. Am J Dig Dis 1978; 23: 398-406
14. Van der Rijt CC, Schalm SW, De Groot GH, De Vlieger M. Objective measurement of hepatic encephalopathy by means of automated EEG analysis. Electroencephalogr Clin Neurophysiol 1984; 57: 423-426
15. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Brit J Surg 1973; 60: 646-649
16. Da Fonseca-Wollheim F. Direct determination of plasma ammonia without deproteinization. An improved enzymic determination of ammonia, II (author's transl). Z Klin Chem Klin Biochem 1973; 11: 426-431
17. Butterworth RF, Giguere JF, Michaud J, Lavoie J, Layrargues GP. Ammonia: key factor in the pathogenesis of hepatic encephalopathy. Neurochem Pathol 1987; 6: 1-12
18. Lockwood AH, Yap EW, Wong WH. Cerebral ammonia metabolism in patients with severe liver disease and minimal hepatic encephalopathy. J Cereb Blood Flow Metab 1991; 11: 337-341
19. O'Connor JE, Costell M, Miguez MP, Portoles M, Grisolia S. Effect of L-carnitine on ketone bodies, redox state and free amino acids in the liver of hyperammonemic mice. Biochem Pharmacol 1987; 36: 3169-3173
20. Michalak A, Qureshi IA. Plasma and urinary levels of carnitine in different experimental models of hyperammonemia and the effect of sodium benzoate treatment. Biochem Med Metab Biol 1990; 43: 163-174
21. Ratnakumari L, Qureshi IA, Butterworth RF. Effect of L-carnitine on cerebral and hepatic energy metabolites in congenitally hyperammonemic sparse-fur mice and its role during benzoate therapy Metabolism 1993; 42: 1039-1046
22. Basile AS, Jones EA. Ammonia and GABA-ergic neurotransmission: interrelated factors in the pathogenesis of hepatic encephalopathy. Hepatology 1997; 25: 1303-1305
23. Norenberg MD. Astrocytic-ammonia interactions in hepatic encephalopathy. Semin Liver Dis 1996; 16: 245-253
24. Chapa AM, Fernandez JM, White TW, Bunting LD, Gentry LR, Ward TL, Blum SA. Influence of intravenous L-carnitine administration in sheep preceding an oral urea drench. J Anim Sci 1998; 76: 2930-2937
25. Raskind JY, El-Chaar GM. The role of carnitine supplementation during valproic acid therapy. Ann Pharmacother 2000; 34: 630-638
26. Ohtani Y, Endo F, Matsuda I. Carnitine deficiency and hyperammonemia associated with valproic acid therapy. J Pediatr 1982; 101: 782-785
27. Sugimoto T, Araki A, Nishida N, Sakane Y, Woo M, Takeuchi T, Kobayashi Y. Hepatotoxicity in rat following administration of valproic acid: effect of L-carnitine supplementation. Epilepsia. 1987; 28: 373-377
28. Reitan RM, Wolfson D. The Halstead-Reitan. Neuropsychological test battery: theory and clinical interpretation. Tucson, AZ: Neuropsychology Press; 1993
29. Hearn TJ, Coleman AE, Lai JC, Griffith OW, Cooper AJ. Effect of orally administered L-carnitine on blood ammonia and L-carnitine concentrations in portacaval-shunted rats. Hepatology 1989; 10: 822-828
30. Therrien G, Giguere JF, Butterworth RF. Increased cerebrospinal fluid lactate reflects deterioration of neurological status in experimental portal-systemic encephalopathy. Metab Brain Dis 1991; 6: 231-238
31. Sherratt HS. Acyl-CoA esters of xenobiotic carboxylic acids as biochemically active intermediates. Biochem Soc Trans 1985; 13: 856-858
32. Corkey BE, Hale DE, Glennon MC, Kelley RI, Coates PM, Kilpatrick L, Stanley CA. Relationship between unusual hepatic acyl coenzyme A profiles and the pathogenesis of Reye syndrome. J Clin Invest 1988; 82: 782-788